Showing results (2291-2300 of 6,777) with videos related to
Sort By:
Pageof 678
Clinical Therapeutics|June 28, 2011
Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trialsAnthony R Godfrey, Jennifer Digiacinto, Matthew W DavisClinical Therapeutics|June 28, 2011
Impact of drug label changes on propofol use in pediatrics for moderate conscious sedationPamela C Heaton, Joseph Schuchter, Carole M Lannon, et al.Clinical Therapeutics|June 28, 2011
Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteersFrancisco E Estevez-Carrizo, Susana Parrillo, Mónica Cedres Ercoli, et al.Clinical Therapeutics|January 4, 2011
Challenges and opportunities in establishing scientific and regulatory standards for determining therapeutic equivalence of modified-release products: Workshop summary reportMei-Ling Chen, Vinod P Shah, Derek Ganes, et al.Clinical Therapeutics|January 4, 2011
Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort studyChristopher W Crank, Marc H Scheetz, Benjamin Brielmaier, et al.Clinical Therapeutics|January 4, 2011
Allergic shock and death associated with protamine administration in a diabetic patientYan-Qi Chu, Li-Jian Cai, De-Chun Jiang, et al.Clinical Therapeutics|January 4, 2011
Efficacy and tolerability of enteral formulations of ibuprofen in the treatment of patent ductus arteriosus in preterm infantsJean-Bernard Gouyon, Yves KibleurClinical Therapeutics|January 4, 2011
A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteersZamri Chik, Roma Choudhury Basu, Rokiah Pendek, et al.Clinical Therapeutics|February 15, 2011
Combined retrospective analysis of seven phase II and III trials of the efficacy of linezolid in the treatment of pneumonia caused by multidrug-resistant Streptococcus pneumoniaeM Marian Ijzerman, Kenneth J Tack, David B HuangClinical Therapeutics|February 15, 2011
Nonadherence to oral linezolid after hospitalization: a retrospective claims analysis of the incidence and consequence of claim reversalsAmy T Ball, Yihua Xu, Robert J Sanchez, et al.Pageof 678